|
|
Volumn 11, Issue 9, 2012, Pages 664-
|
|
Trial watch: HIV integrase inhibitor-based regimen beats market leader
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABACAVIR;
COBICISTAT;
DOLUTEGRAVIR;
EFAVIRENZ;
EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
ELVITEGRAVIR;
EMTRICITABINE;
HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;
INTEGRASE INHIBITOR;
LAMIVUDINE;
NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;
RALTEGRAVIR;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
TENOFOVIR;
DISEASE COURSE;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
GASTROINTESTINAL TOXICITY;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
NEUROTOXICITY;
NOTE;
PRIORITY JOURNAL;
UNSPECIFIED SIDE EFFECT;
CLINICAL TRIALS, PHASE III AS TOPIC;
HIV INFECTIONS;
HIV INTEGRASE;
HIV INTEGRASE INHIBITORS;
HIV-1;
HUMANS;
|
|
EID: 84866104965
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3836 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
